News & Partnering

Learn more about Imvax

For more detail on our progress, behind the scenes at Imvax, or opportunities to collaborate with us to advance the future of immunotherapy, dive in below.

Press releases

October 21, 2021

Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC Annual Meeting

PHILADELPHIA (October 21, 2021) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 36th Annual Meeting of the Society... Read more

September 16, 2021

Imvax Appoints John M. Limongelli as Chief Legal Officer

PHILADELPHIA (September 16, 2021) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company’s Chief... Read more

August 9, 2021

Imvax Further Strengthens Leadership Team with Appointment of Josh Muntner as Chief Financial Officer

PHILADELPHIA (August 9, 2021) — Imvax, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of Josh Muntner as the company’s chief financial officer effective... Read more

May 11, 2021

Imvax to present at UBS Global Healthcare Virtual Conference

PHILADELPHIA, PA (May 11, 2021) —Imvax, a clinical stage immuno-oncology company driven to transform patient treatment and outcomes with its novel technology platform, announced that John Furey,... Read more